Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Xenon Xe 133 is an inhaled radioactive noble gas used as a diagnostic imaging agent for pulmonary ventilation studies. It enables visualization of lung function and airflow patterns to detect obstructive and restrictive lung diseases. The agent works by inhalation, allowing real-time assessment of ventilation distribution throughout the lungs.
Product is in late-stage maturity with LOE approaching; commercial teams are likely focused on transition planning and maintaining existing hospital/imaging center relationships rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Xenon Xe 133 offers stable career exposure in the diagnostic imaging and radiopharmaceutical space, but limited growth opportunity due to LOE proximity. Roles emphasize customer relationship management, clinical education, and transition planning rather than market expansion.
Worked on XENON XE 133-V.S.S. at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.